{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:49:23Z","timestamp":1760906963209,"version":"3.41.2"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1111\/igc.0b013e3181a8b938","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T13:36:56Z","timestamp":1291383416000},"page":"1137-1141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"B.L.","family":"Rapoport","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.A.","family":"Vorobiof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Slabber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.S.","family":"Hlophe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181a8b938_bb0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bpobgyn.2005.10.007","article-title":"Worldwide burden of gynecologic cancer: the size of the problem","volume":"20","author":"Sankaranarayanan","year":"2006","journal-title":"Best Pract Res Clin Obstet Gynecol."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0010","doi-asserted-by":"crossref","first-page":"ii12","DOI":"10.1093\/annonc\/mdm017","volume":"18","author":"ESMO Guidelines Working Group","year":"2007","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0020","doi-asserted-by":"crossref","first-page":"263Y268","DOI":"10.1093\/annonc\/mdl376","article-title":"Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial","volume":"18","author":"Ferrero","year":"2007","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0025","doi-asserted-by":"crossref","first-page":"518Y525","DOI":"10.1016\/j.ygyno.2007.08.008","volume":"107","author":"du Bois","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2007.08.075","volume":"108","author":"Alberts","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ygyno.2005.08.020","article-title":"Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer","volume":"100","author":"Nicoletto","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0040","first-page":"21","article-title":"Phase I trial of pegylated-liposomal doxorubicin (Caelyx, Doxil) and carboplatin in patients with advanced malignancy. Proc Am Soc","author":"Uys","year":"2002","journal-title":"Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0045","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.5555","article-title":"Phase II study of combination therapy with pegylated liposomal doxorubicin (PLD) and carboplatin in patients (pts) with relapsed, platinum sensitive and platinum semi-sensitive ovarian cancer","author":"Rapoport","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0050","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"6","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0055","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.1073\/pnas.88.24.11460","article-title":"Sterically stabilized liposomes: improvement in pharmacokinetics and anti-tumour therapeutic efficacy","volume":"88","author":"Papahadjopoulous","year":"1991","journal-title":"Proc Natl Acad Sci."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0060","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol."},{"year":"2008","series-title":"Raritan,NJ: Ortho Biotech Products PL","author":"Doxil (Doxorubicin HCl Liposomal Injection) [product information]","key":"10.1111\/IGC.0b013e3181a8b938_bb0065"},{"author":"Cancer Therapy Evaluation Program","key":"10.1111\/IGC.0b013e3181a8b938_bb0070"},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0075","first-page":"3040","article-title":"Phase I study of Doxil-cisplatin combination chemotherapy in patients with advanced malignancies","volume":"7","author":"Lyass","year":"2001","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0080","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicinYassociated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"Von Moos","year":"2008","journal-title":"Eur J Cancer."},{"key":"10.1111\/IGC.0b013e3181a8b938_bb0085","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181a8b938","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24155004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24155004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1111\/IGC.0b013e3181a8b938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:07:54Z","timestamp":1753232874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24155004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S1048891X24155004"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181a8b938","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181a8b938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2009 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}